Alteogen acquires U.S. formulation patent of biosimilar referencing ‘Eylea’

Alteogen officially announced on the 30^th that the company acquired a U.S. patent of a stable liquid formulation of fusion protein with IgG Fc domain on 27 April.

According to the company, the patent, formulation technology of a biosimilar referencing Eylea, a macular degeneration therapy, is a patent which keeps stabilization of protein drugs containing antibodies.

“The original Eylea’s subs...